#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic graft versus host disease in intestine Anal cancer recurrent PIK3CA-activated mutation Anti-HLA antibody test positive Amyotrophic lateral sclerosis Alveolar proteinosis Congenital megacolon Small intestine leiomyosarcoma PIK3CA related overgrowth spectrum Parkinson's disease IgA nephropathy Intracranial calcification Chronic lymphocytic leukaemia refractory Cystic fibrosis Retinoblastoma More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma refractory – Life with Disease Familial amyotrophic lateral sclerosis – Diagnostics Cholangitis sclerosing Mucopolysaccharidosis I – Basic Information Shprintzen-Goldberg syndrome – Diagnostics Retinoblastoma – Treatment Epidermolysis bullosa – Trials in Disease Amyotrophic lateral sclerosis – Diagnostics Adrenocortical carcinoma – Trials in Disease Carcinoid syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Belumosudil Mesilate Naproxen TRONTINEMAB GSKVX000000048110 Amsacrine Spartalizumab Tofogliflozin HSP-CAR19M Aztreonam Naxitamab Calcium Levofolinate ISPAGHULA HUSK IHMA-2121908-1 Hydroxocobalamin Lonvoguran ELTANEXOR Fitusiran Poltreg-T1D Lutetium (177Lu) Edotreotide Eptinezumab More therapies…

    Learn about Your Condition

    Psychotic behaviour Influenza Asymptomatic HIV infection Alpha-1 antitrypsin deficiency Klinefelter's syndrome Ovarian cancer metastatic Juvenile absence epilepsy Acute myeloid leukaemia Benign renal neoplasm Cerebrovascular accident Large cell lung cancer stage 0 Suicidal ideation Hepatorenal syndrome Polycythaemia vera Nodal osteoarthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study of Erlotinib and LY2875358 for Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Mutations After Initial Erlotinib Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Emibetuzumab
    • Erlotinib
    Germany Spain

  • Study on the Safety and Effectiveness of Fianlimab, Cemiplimab, and Chemotherapy in Adults with Resectable Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Fianlimab
    • Carboplatin
    • Cemiplimab
    France Germany Italy Romania Spain

  • Study of Pembrolizumab, Pemetrexed, and Carboplatin for Patients with Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    • Pembrolizumab
    The Netherlands

  • Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Osimertinib
    Lithuania Norway Sweden

  • Study on Bevacizumab and Erlotinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Bevacizumab
    • Erlotinib
    Italy

  • Study of Durvalumab with Chemoradiation Therapy for Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Saline
    • Pemetrexed Disodium
    • Carboplatin
    Hungary Poland
Previous Page
1 … 30 31 32 33 34 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!